EQH Maintained by Wells Fargo -- Price Target Raised to $65.00

Equitable Holdings (EQH) added a bitcoin-linked investment option to its retirement annuity, tracking the iShares Bitcoin Trust ETF (IBIT). The option offers downside protection with buffers of 10% to 40% and caps allocations at 25%. Equitable reported $1.7B in net inflows for Retirement, $2.0B for Wealth Management, and $0.8B for Asset Management in Q2 2026, with total assets under management reaching $1.2T. The company also reported a GAAP net loss of $453M but positive non-GAAP operating earn

Equitable Holdings (EQH) discussed its Q2 2026 earnings call and progress on its merger with Corebridge. Shareholders approved the deal on July 30 with over 97% support, and federal antitrust review is complete. EQH reported non-GAAP operating EPS of $1.70, up 24% YoY, and $1.2T AUM. It returned $449M to shareholders, including $366M buybacks.

Equitable Holdings, Inc. (EQH) filed an SEC Form 8-K — Results of Operations and Financial Condition. EQUITABLE HOLDINGS REPORTS SECOND QUARTER 2026 RESULTS _______________________________________ • Merger with Corebridge Financial approved by shareholders on July 30th and on track to close by year-end 2026 • Positive organic growth across all businesses with net inflows of $1.7

Chevron and Egypt's Ministry of Petroleum announced positive results from the Nargis-2 gas well in the Mediterranean. The well confirmed extended gas-bearing reservoirs and an additional gas interval, supporting further appraisal and development. Chevron operates the area with partners Eni, Mubadala Energy, and Tharwa Petroleum. The well reached 5,000 meters with 35 meters of net gas pay, indicating potential for further development.

Genmab and Incyte are collaborating on clinical trials for metastatic colorectal cancer. The trials will evaluate the combination of Genmab's petosemtamab and Incyte's INCB161734 with standard chemotherapy. Petosemtamab targets EGFR and LGR5, while INCB161734 inhibits KRAS G12D. The companies aim to provide a new treatment option for patients with KRAS G12D-mutated metastatic colorectal cancer.

Incyte (INCY) and Genmab (GMAB) are collaborating on a clinical trial to evaluate Incyte's KRAS G12D inhibitor INCB161734 with Genmab's bispecific antibody petosemtamab and standard chemotherapy for metastatic colorectal cancer with KRAS G12D mutation. The Phase 1/2 study will be co-funded by both companies, with Genmab conducting the trial and Incyte providing the clinical supply of INCB161734. This collaboration aims to address a significant unmet medical need in this patient population.